Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcGrath, Shannon-
dc.contributor.authorChristidis, Daniel-
dc.contributor.authorPerera, Marlon-
dc.contributor.authorHong, Sung Kyu-
dc.contributor.authorManning, Todd G-
dc.contributor.authorVela, Ian-
dc.contributor.authorLawrentschuk, Nathan-
dc.identifier.citationProstate International 2016; 4(4): 130-135en_US
dc.description.abstractPURPOSE: Localised prostate cancer diagnosis and management is increasingly complex due to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer. Such tools may be able to distinguish clinically significant cancers from less aggressive variants to assist with prostate cancer risk stratification and guide decisions and healthcare algorithms. We aimed to provide a comprehensive review of the current prostate cancer biomarkers available and in development. METHODS: MEDLINE and EMBASE databases searches were conducted to identify articles pertaining to the use of novel biomarkers for prostate cancer. RESULTS: A growing number of novel biomarkers are currently under investigation. Such markers include urinary biomarkers, serology-based markers or pathological tissue assessments of molecular and genetic markers. While limited clinical data is present for analysis, early results appear promising. Specifically, a combination of serum and urinary biomarkers (Serum PSA + Urinary PCA3 + Urinary TMPRSS2-ERG fusion) appears to provide superior sensitivity and specificity profiles compared to traditional diagnostic approaches (AUC 0.88). CONCLUSION: The accurate diagnosis and risk stratification of prostate cancer is critical to ensure appropriate intervention. The development of non-invasive biomarkers can add to the information provided by current screening practices and allows for individualised risk stratification of patients. The use of these biomarkers appears to increase the sensitivity and specificity of diagnosis of prostate cancer. Further studies are necessary to define the appropriate use and time points of each biomarker and their effect on the management algorithm of prostate cancer.en_US
dc.subjectProstate canceren_US
dc.subjectProstate specific antigenen_US
dc.titleProstate cancer biomarkers: are we hitting the mark?en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleProstate Internationalen_US
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Urology, Seoul National University Bundang Hospital, Seoul, South Koreaen_US
dc.identifier.affiliationDepartment of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationQueensland University of Technology, Australian Prostate Cancer Research Center-Queensland, Brisbane, Australiaen_US
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australiaen_US
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.